EUCTR2007-005203-18-GR进行中（未招募）不适用
An open Phase II study of immunization with the recMAGE-A3 + AS01B Antigen-Specific Cancer Immunotherapeutic in patients with MAGE-A3-positive unresectable and progressive metastatic cutaneous melanoma. - MAGE3-AS01B-MEL-001 (MET)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 34
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female patient with histologically proven, measurable metastatic cutaneous melanoma, and with documented progressive disease within the 12 weeks before the first administration of study treatment.
- •2. Written informed consent has been obtained from the patient before the performance of any protocol-specific procedure.
- •3. Patient is 18 years or older at the time of signature of the informed consent.
- •4. The patient’s tumor shows expression of MAGE-A3 gene.
- •5. ECOG performance status of 0 or 1.
- •6. The patient has normal organ functions shown by the lab values.
- •7. If the patient is female, she must be of non-childbearing potential, i.e. have a current tubal ligation, hysterectomy, ovariectomy or be post menopausal, or if she is of childbearing potential, she must practice adequate contraception for 30 days prior to administration of study treatment, have a negative pregnancy test and continue such precautions during all study treatment period and for 2 months after completion of the injection series.
- •8. In the view of the investigator, the patient can and will comply with the requirements of the protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. The patient has at any time received systemic (bio-)chemotherapy (except for isolated limb perfusion, as long as this was performed at least 4 weeks before first study treatment administration).
- •2. The patient is scheduled to receive any anti-cancer specific treatment, including radiotherapy, immunotherapy, chemotherapy and immunomodulating agents.
- •3. The patient requires concomitant treatment with systemic corticosteroids, or any other immunosuppressive agents.
- •The use of prednisone, or equivalent, less than 0.5 mg/kg/day (absolute maximum 40 mg/day), or inhaled corticosteroids for COPD or topical steroids is permitted.
- •4. The patient received any cancer immunotherapeutic containing a MAGE-A3 antigen or any cancer immunotherapeutic for his/her metastatic disease.
- •Note: Previous adjuvant treatment with a cancer immunotherapeutic containing a tumor antigen other than MAGE-A3 is allowed if the last administration took place at least eight weeks before the first ASCI administration in the present study.
- •5. The patient has received any investigational or non-registered drug or vaccine other than the study medication within the 30 days preceding the first ASCI injection or it is planned that (s)he will receive such a drug during the study period.
- •6. The patient has (or has had) previous or concomitant malignancies at other sites, except effectively treated malignancy that is considered by the investigator highly likely to have been cured.
- •7. History of allergic disease or reactions likely to be exacerbated by any component of the study investigational product.
- •8. The patient has an autoimmune disease such as, but not limited to, multiple sclerosis, lupus, and inflammatory bowel disease. Patients with vitiligo are not excluded.
- •9. The patient has a family history of congenital or hereditary immunodeficiency.
- •10. The patient is known to be positive for the Human Immunodeficiency Virus (HIV).
- •11. The patient has psychiatric or addictive disorders that may compromise his/her ability to give informed consent, or to comply with the trial procedures.
- •12. The patient has concurrent severe medical problems, unrelated to the malignancy, that would significantly limit full compliance with the study or expose the patient to unacceptable risk.
- •13. For female patients: the patient is pregnant or lactating.
研究者
相似试验
进行中（未招募）
1 期
A Study of Safety and Clinical Activity of Cancer Immunotherapy Plus Chemotherapy in Metastatic Melanoma PatientsPatients with unresectable and progressive metastatic cutaneous melanoma, whose tumor expresses MAGE-A3.MedDRA version: 16.0Level: LLTClassification code 10027481Term: Metastatic melanomaSystem Organ Class: 100000004864EUCTR2008-001918-25-BEGlaxoSmithKline Biologicals40
进行中（未招募）
1 期
A Study of Safety and Clinical Activity of Cancer Immunotherapy Plus Chemotherapy in Metastatic Melanoma PatientsEUCTR2008-001918-25-FRGlaxoSmithKline Biologicals48
已完成
不适用
An open Phase I Study of immunization with the recNY-ESO-1 + AS15 Antigen-Specific Cancer Immunotherapeutic in patients with NY-ESO-1-positive unresectable and progressive metastatic cutaneous melanoma.skin cancer10040900melanomaNL-OMON41308GlaxoSmithKline6
进行中（未招募）
不适用
Randomized, open phase II study of immunization with the recombinant MAGE-3 protein combined with adjuvant AS02B or AS15 in patients with unresectable and progressive metastatic cutaneous melanoma.nresectable and progressive metastatic cutaneous melanomaMedDRA version: 9.1Level: LLTClassification code 10027480Term: Metastatic malignant melanomaEUCTR2004-001937-40-ITE.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER68
进行中（未招募）
1 期
Randomized, open phase II study of immunization with the recombinant MAGE-3 protein combined with adjuvant AS02B or AS15 in patients with unresectable and progressive metastatic cutaneous melanomanresectable and progressive metastatic cutaneous melanomaMedDRA version: 7.0Level: LLTClassification code 10027155EUCTR2004-001937-40-ESEuropean Organisation for Research and Treatment of Cancer